z-logo
Premium
Five‐year study of quality of life in myotonic dystrophy
Author(s) -
Peric S.,
Vujnic M.,
Dobricic V.,
Marjanovic A.,
Basta I.,
Novakovic I.,
Lavrnic D.,
RakocevicStojanovic V.
Publication year - 2016
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12549
Subject(s) - medicine , myotonic dystrophy , quality of life (healthcare) , physical therapy , weakness , cohort , sf 36 , muscular dystrophy , rating scale , muscle weakness , cohort study , pediatrics , disease , health related quality of life , surgery , psychology , developmental psychology , nursing
Background – Myotonic dystrophy type 1 ( DM 1) is the most common muscular dystrophy in adults. There is a complete lack of studies that assessed quality of life (QoL) trajectory during time in DM 1 cohorts. Aim – To analyze changes of QoL in patients with DM 1 during a 5‐year follow‐up period and to assess responsiveness of the SF ‐36 questionnaire. Patients and Method – At the baseline, this study comprised 84 DM 1 patients, of whom 62 were retested after the mean period of 64.2 ± 3.9 months. Severity of muscular weakness was assessed using the Muscular Impairment Rating Scale ( MIRS ). Patients completed Serbian version of the SF ‐36 questionnaire as a measure of health‐related QoL. Results – After 5 years, MIRS score of our DM 1 patients showed significant progression of 0.5 grade ( P  < 0.01). All mental subdomains, role physical, and total SF ‐36 scores significantly improved after 5 years ( P  < 0.01). Unexpectedly, worsening of muscular weakness from mild to severe was in association with improvement of QoL. Conclusion – QoL improved in our cohort of DM 1 patients during a 5‐year period despite the progression of the disease. SF ‐36 should be used with caution as a patient‐reported outcome measure in DM 1 clinical trials.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom